Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-901-9 | CAS number: 7778-39-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Study period:
- 1987
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 987
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- In a toxicokinetic study, groups of pregnant CD-1 mice were administered with sodium arsenate (As+5) at 20 (i.p.) or 40 (p.o.) mg/kg bw on gestation Day 18 and all tissues were analysed for arsenic levels at intervals up to 24 hours following treatment.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Disodium hydrogenarsenate
- EC Number:
- 231-902-4
- EC Name:
- Disodium hydrogenarsenate
- Cas Number:
- 7778-43-0
- IUPAC Name:
- disodium hydrogen arsenate
- Details on test material:
- - Name of test material (as cited in study report): Sodium arsenate
- Source: Fisher Scientific, Atlanta, USA
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- female
Administration / exposure
- Route of administration:
- other: intraperitoneal and oral (gavage)
- Vehicle:
- water
- Duration and frequency of treatment / exposure:
- Single dose
Doses / concentrations
- Remarks:
- Doses / Concentrations:
- Intraperitoneal: 20 mg/kg bw
- Oral gavage: 40 mg/kg bw
- No. of animals per sex per dose / concentration:
- No data
- Control animals:
- no
Results and discussion
- Preliminary studies:
- No data
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- No data
- Details on distribution in tissues:
- - Following sodium arsenate administration, arsenic was detected in every sample obtained regardless of sampling time or treatment route, with the exceptions of 10 minute and 24-hour urines. All samples had declined to their lowest arsenic levels by 18-24 hours.
INTRAPERITONEAL ADMINISTRATION (As-IP):
- Total arsenic levels peaked in maternal blood, liver, kidney and urine at 10 minutes, 0.5 hours, 20 minutes and 1 hour respectively.
- Fetal and placental arsenic were highest at 2 hours.
ORAL ADMINISTRATION (As-PO):
- Maternal blood and solid tissue samples peaked at 1 hour, while urine values were highest at 2 hours after treatment.
- Fetal and placental arsenic were highest at 6 hours and 1 hour, respectively.
Transfer into organs
- Test no.:
- #1
- Transfer type:
- blood/placenta barrier
- Observation:
- distinct transfer
- Details on excretion:
- - Arsenic distribution in maternal samples was essentially complete at 0.5 hour and was followed by uniform washout in the blood, kidney and urine over the remaining period of study. Following an initial rapid uptake and distribution phase, both groups exhibited essentially linear elimination, showing some tendency toward tailing after 12 hours.
- Arsenic elimination in liver, kidneys and blood was fitted to a first-order one-compartment model with an elimination rate constant for the various tissues of ~0.06 and 0.04 hr-1 for As-IP and As-PO groups, respectively. Disappearance of arsenic from urine showed a parallel rate of elimination.
- Biological half-life for arsenic in maternal tissues was estimated at approximately 10 days for both groups.
- Arsenic was found to be reasonably homogeneous in its tissue distribution.
Toxicokinetic parameters
- Test no.:
- #1
- Toxicokinetic parameters:
- half-life 1st: 10 hours
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Arsenic metabolites (mono and dimethyl arsenic) were found in the fetuses up to 83% of total fetal arsenicals by 24 hours.
Any other information on results incl. tables
Table 1: Arsenic content of maternal samples following i.p. (20 mg/kg bw) or p.o. (40 mg/kg bw) sodium arsenate administration to mice on gestation Day 18
Sampling time (hour) |
Sample assayed and route of exposure1 |
|||||||
Liver2 |
Kidneys2 |
Blood3 |
Urine3 |
|||||
i.p. |
p.o. |
i.p. |
p.o. |
i.p |
p.o. |
i.p. |
p.o. |
|
10 min |
3.79 ± 1.13 |
NA4 |
20.41 ± 3.61 |
NA |
6.93 ± 1.00 |
NA |
0 |
NA |
20 min |
5.43 ± 0.78 |
NA |
25.39 ± 1.30 |
NA |
2.97 ± 0.49 |
NA |
115.30 ± 62.56 |
NA |
0.5 |
7.85 ± 4.65 |
7.18 ± 2.40 |
23.76 ± 4.05 |
9.77 ± 0.24 |
3.45 ± 0.93 |
1.80 ± 0.26 |
294.905 |
195.30 ± 190.42 |
1 |
3.19 ± 2.95 |
11.70 ± 3.44 |
9.33 ± 7.80 |
11.04 ± 2.29 |
1.92 ± 0.54 |
2.05 ± 1.05 |
712 .305 |
304.30 ± 264.96 |
2 |
3.66 ± 1.12 |
9.17 ± 5.41 |
9.35 ± 2.87 |
6.95 ± 2.23 |
1.68 ± 1.09 |
0.83 ± 0.35 |
168.605 |
341.50 ± 274.27 |
4 |
2.91 ± 1.62 |
2.55 ± 0.58 |
5.89 ± 2.11 |
5.10 ± 1.07 |
1.13 ± 0.65 |
0.57 ± 0.16 |
234.20 ± 160.92 |
237.90 ± 162.14 |
6 |
0.99 ± 0.57 |
4.27 ± 3.18 |
1.81 ± 1.02 |
5.07 ± 2.68 |
0.53 ± 0.08 |
0.81± 0.14 |
29.405 |
302.505 |
12 |
0.28 ± 0.09 |
1.14 ± 0.50 |
0.47 ± 0.18 |
1.90 ± 1.54 |
0.10 ± 0.03 |
0.32 ± 0.16 |
46.80 ± 43.99 |
75.00 ± 60.57 |
18 |
0.14 ± 0.11 |
0.62 ± 0.12 |
0.28 ± 0.21 |
0.78 ± 0.02 |
0.07 ± 0.08 |
0.17 ± 0.06 |
10.30 ± 3.71 |
54.50 ± 11.01 |
24 |
0.14 ± 0.04 |
0.69 ± 0.35 |
0.23 ± 0.13 |
1.19 ± 0.77 |
0.06 ± 0.04 |
0.25 ± 0.17 |
0 |
0 |
1 Each value represents the mean ± SD for samples from three or more individuals.
2 µg As/g wet weight
3 µg As/mL
4 Not available
5 Three urine samples were not available for all sampling times and SDs were not calculated in such cases.
Table 2: Arsenic content of fetal tissues following i.p. (20mg/kg bw) or p.o. (40 mg/kg bw) sodium arsenate administration to mice on gestation Day 18
Tissues assayed and route of exposure1 |
||||
Sampling time (hour) |
Placentas2 |
Fetuses2 |
||
|
i.p. |
p.o. |
i.p. |
p.o |
10 min |
2.49 ± 1.21 |
NA |
0.18 ± 0.08 |
NA |
20 min |
3.06 ± 1.71 |
NA |
0.40 ± 0.07 |
NA |
0.5 |
3.54 ± 2.54 |
1.04 ± 0.32 |
0.78 ± 0.26 |
0.14 ± 0.05 |
1 |
8.46 ± 5.22 |
2.27 ± 0.57 |
1.25 ± 1.09 |
0.56 ± 0.24 |
2 |
9.30 ± 4.32 |
1.95 ± 0.38 |
3.49 ± 2.95 |
0.56 ± 0.18 |
4 |
5.01 ± 2.46 |
1.14 ± 0.27 |
2.92 ± 2.29 |
0.51 ± 0.17 |
6 |
4.82 ± 1.91 |
1.72 ± 0.54 |
1.12 ± 0.87 |
0.77 ± 0.27 |
12 |
0.59 ± 0.33 |
0.69 ± 0.19 |
1.08 ± 1.48 |
0.48 ± 0.05 |
18 |
0.26 ± 0.14 |
0.68 ± 0.38 |
0.33 ± 0.22 |
0.38 ± 0.05 |
24 |
0.74 ± 0.55 |
0.57 ± 0.23 |
0.22 ± 0.08 |
0.33 ± 0.09 |
1 Each value represents the mean ± SD of samples from three or more litter
2 µg As/g
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
Under the test conditions, arsenate injection (i.p.) induces very high concentration peak in the conceptus when compared to oral route and reproductive studies conducted by this route should be interpreted in the light of this finding. - Executive summary:
In a toxicokinetic study, groups of pregnant CD-1 mice were administered with sodium arsenate (As+5) at 20 (i.p.) or 40 (p.o.) mg/kg bw on gestation Day 18. Individual fetuses, pooled placentas and maternal blood, urine, liver and kidneys were obtained from three or more litters at intervals up to 24 hours following treatment. Acid-digested samples were analyzed for total arsenic by hydride generation atomic absorption spectrophotometry. Also fetuses were analyzed for the arsenic metabolites.
Administration route did not affect the rate of arsenic elimination from various maternal samples. First-order elimination followed a brief period of distribution and the biological half-life was approximately 10 hours. Arsenic was found in most samples, with mean peak concentrations expressed as µg/g (wet wt.) or /mL (values listed are post-treatment sampling times in minutes or hours and concentrations for i.p. and for p.o. treated groups, respectively) as follows: fetuses-2, 3.5; 6, 0.8, placentas-2, 9.3; 1, 2.3, blood-10 minutes, 6.9; 1, 2.0, urine-1, 712; 2, 342, kidney-20 minutes, 25.4; 1, 11.0, liver-0.5, 7.9; 1, 11.7. Arsenic levels in fetuses and placentas had declined to 0.22 µg/g and 0.74 µg/g for i.p. and 0.33 µg/g and 0.57 µg/g for p.o. treatments, respectively in 24 hours. Fetal arsenic uptake and loss were more rapid following i.p. than p.o. and peak fetal As+5 was almost five fold higher following i.p. treatment. Arsenic metabolites (MMA and DMA) were found in the fetuses up to 83% of total fetal arsenicals by 24 hours.
Under the test conditions, arsenate injection (i.p.) induces very high concentration peak in the conceptus when compared to oral route and reproductive studies conducted by this route should be interpreted in the light of this finding.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
